- Home
- ALDX vs NCV Comparison
ALDX vs NCV Comparison
Compare ALDX & NCV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALDX
- NCV
- Stock Information
- Founded
- ALDX 2004
- NCV 2003
- Country
- ALDX United States
- NCV United States
- Employees
- ALDX N/A
- NCV N/A
- Industry
- ALDX Biotechnology: Pharmaceutical Preparations
- NCV Finance Companies
- Sector
- ALDX Health Care
- NCV Finance
- Exchange
- ALDX Nasdaq
- NCV Nasdaq
- Market Cap
- ALDX 160.8M
- NCV 317.4M
- IPO Year
- ALDX 2014
- NCV N/A
- Fundamental
- Price
- ALDX $4.76
- NCV $14.16
- Analyst Decision
- ALDX Strong Buy
- NCV
- Analyst Count
- ALDX 2
- NCV 0
- Target Price
- ALDX $9.50
- NCV N/A
- AVG Volume (30 Days)
- ALDX 1.2M
- NCV 405.1K
- Earning Date
- ALDX 07-31-2025
- NCV 01-01-0001
- Dividend Yield
- ALDX N/A
- NCV 12.48%
- EPS Growth
- ALDX N/A
- NCV N/A
- EPS
- ALDX N/A
- NCV N/A
- Revenue
- ALDX N/A
- NCV N/A
- Revenue This Year
- ALDX N/A
- NCV N/A
- Revenue Next Year
- ALDX N/A
- NCV N/A
- P/E Ratio
- ALDX N/A
- NCV N/A
- Revenue Growth
- ALDX N/A
- NCV N/A
- 52 Week Low
- ALDX $1.14
- NCV $2.84
- 52 Week High
- ALDX $7.20
- NCV $3.59
- Technical
- Relative Strength Index (RSI)
- ALDX 78.74
- NCV 62.28
- Support Level
- ALDX $4.12
- NCV $14.06
- Resistance Level
- ALDX $4.60
- NCV $14.35
- Average True Range (ATR)
- ALDX 0.29
- NCV 0.14
- MACD
- ALDX 0.08
- NCV 0.01
- Stochastic Oscillator
- ALDX 90.91
- NCV 76.22
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
About NCV Virtus Convertible & Income Fund of Beneficial Interest
Virtus Convertible & Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and high current income. It intends to achieve the objective by investing in a portfolio of domestic convertible securities and non-convertible income-producing securities. Its portfolio of investments includes Software, the Internet, the Commercial Services sector in the form of Convertible Bonds and Notes, and Media, Oil, Gas & Consumable Fuels, and Entertainment sector in the form of Corporate Bonds and Notes.